Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213, USA.
J Neurosurg Spine. 2010 Apr;12(4):357-71. doi: 10.3171/2009.10.SPINE09208.
Patients with radiculopathy, with or without back pain, often do not respond to conservative care and may be considered for epidural steroid injection therapy or a disc decompression procedure. Plasma disc decompression (PDD) using the Coblation SpineWand device is a percutaneous, minimally invasive interventional procedure. The purpose of this study was to evaluate clinical outcomes with PDD as compared with standard care using fluoroscopy-guided transforaminal epidural steroid injection (TFESI) over the course of 2 years.
This was a multicenter randomized controlled clinical study. Ninety patients (18-66 years old) who had sciatica (visual analog scale score > or = 50) associated with a single-level lumbar contained disc herniation were enrolled. In all cases, their condition was refractory to initial conservative care and 1 epidural steroid injection had failed. Participants were randomly assigned to receive either PDD (46 patients) or TFESI (44 patients, up to 2 injections).
The patients in the PDD Group had significantly greater reduction in leg pain scores and significantly improved Oswestry Disability Index and 36-Item Short Form Health Survey ([SF-36], physical function, bodily pain, social function, and physical components summary) scores than those in the TFESI Group. During the 2-year follow-up, 25 (56%) of the patients in the PDD Group and 11 (28%) of those in the TFESI Group remained free from having a secondary procedure following the study procedure (log-rank p = 0.02). A significantly higher percentage of patients in the PDD Group showed minimum clinically important change in scores for leg and back pain and SF-36 scores that exceeded literature-based minimum clinically important changes. Procedure-related adverse events, including injection site pain, increased leg or back pain, weakness, and lightheadedness, were observed in 5 patients in the PDD Group (7 events) and 7 in the TFESI Group (14 events).
In study patients who had radicular pain associated with a contained lumbar disc herniation, those patients treated with PDD had significantly reduced pain and better quality of life scores than those treated using repeated TFESI. In addition, significantly more PDD patients than TFESI patients avoided having to undergo a secondary procedure during the 2-year study follow-up.
患有根性神经病(伴有或不伴有背痛)的患者通常对保守治疗无反应,可能会考虑接受硬膜外类固醇注射治疗或椎间盘减压手术。等离子椎间盘减压术(PDD)使用 Coblation SpineWand 设备是一种经皮、微创介入性程序。本研究的目的是评估与使用透视引导下经椎间孔硬膜外类固醇注射(TFESI)的标准护理相比,PDD 在 2 年过程中的临床结果。
这是一项多中心随机对照临床试验。90 名患者(18-66 岁)患有坐骨神经痛(视觉模拟评分>或=50),伴单节段腰椎间盘突出症。在所有情况下,他们的病情都对初始保守治疗有抗性,并且 1 次硬膜外类固醇注射失败。参与者被随机分配接受 PDD(46 例)或 TFESI(44 例,最多 2 次注射)。
PDD 组患者的腿部疼痛评分显著降低,Oswestry 残疾指数和 36 项简短健康调查问卷(SF-36,身体功能、身体疼痛、社会功能和身体成分综合评分)评分显著改善。在 2 年的随访期间,PDD 组的 25 名(56%)患者和 TFESI 组的 11 名(28%)患者在研究后无需进行二次手术(对数秩检验,p=0.02)。PDD 组患者腿部和背部疼痛以及 SF-36 评分的最小临床重要变化比例显著高于文献中基于最小临床重要变化的比例。在 PDD 组中有 5 名患者(7 次事件)和 TFESI 组中有 7 名患者(14 次事件)出现了与程序相关的不良反应,包括注射部位疼痛、腿部或背部疼痛、虚弱和头晕。
在患有神经根性疼痛伴腰椎间盘突出症的研究患者中,与接受重复 TFESI 治疗的患者相比,接受 PDD 治疗的患者疼痛明显减轻,生活质量评分更好。此外,与接受 TFESI 治疗的患者相比,PDD 治疗的患者在 2 年的研究随访期间需要进行二次手术的比例显著降低。